In advanced NSCLC patients who treated with PD-1 blockade, Zer and colleagues have demonstrated that the baseline NLR ≤ 4 was closely related to better disease control rate, lasting treatment duration, and overall survival compared to patients with baseline NLR > 4 [155]. Here, PDCD1 is linked to non-small cell lung carcinoma.